Table 5.
Studies of methotrexate (MTX)-based chemotherapy without radiation in elderly primary CNS lymphoma patients
| Measure | Hoang-Xuan et al.13 | Omuro et al.16 | Freilich et al.15 | Ng et al.14 | Gavrilovic et al.18,a | Present Study |
|---|---|---|---|---|---|---|
| Number of patients | 50 | 23 | 13 | 10 | 26 | 31 |
| Dose of MTX | 1 g/m2 | 3 g/m2 | 1–3.5 g/m2 | 3.5–8 g/m2 | 3.5 g/m2 | 3.5–8 g/m2 |
| Median age (range), years | 72 (60–81) | 68 (60–79) | 74 (54–89) | 72.5 (66–75) | 65 (22–89) | 74 (70–85) |
| Radiographic response | 48% | 55% | 92% | 90% | NA | 96.7% |
| Median progression-free survival (months) | 10.6 | 8 | NA | NA | 7 | 7.1 |
| Median overall survival (months) | 14.3 | 35 | 30.5 | 36 | 29 | 37 |
Abbreviation: NA, not reported. Only Ng et al.14 and our study used MTX monotherapy. Most patients (87%) received 8 g/m2 of MTX in our study.
a
Four of the 26 patients treated with chemotherapy alone were <60 years old.